Komodo Health Announces Clinical Development Agreement with Janssen
Komodo Health has announced a new client engagement with Janssen. Janssen Research & Development, LLC (Janssen) will be using Komodo's real-world data and AI software. Janssen plans to use Komodo's services aiming to improve feasibility, site selection and patient recruitment for clinical trials.
The partnership will focus on offering real-time visibility into patient volumes, the ability to identify trial sites, increasing target recruitment, understanding patient cohorts before launch and reaching diverse patient populations. Janssen will utilize Komodo’s Healthcare Map of 325M U.S. de-identified patient journeys, the largest of any health IT company, and Komodo's industry solutions Prism, Sentinel, and Pulse.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
